Position in SVTR
Snapshot 2026-10-25- Startup SignalsTop 25%–
- Life SciencesTop 10%
- AI for ScienceTop 25%
- Drug Discovery#10of 58
About
Pathos AI, founded in 2022 in Chicago, USA, leverages artificial intelligence and robotic automation to accelerate the development of targeted therapies for solid tumors.
Technology & BusinessWhat · How · Which stage
Research AreasLife SciencesMedicine & PharmaMediumEvidence
运用人工智能与机器人自动化加速实体肿瘤靶向药物的研发
Source：Official site · Updated 2026-09-10 · View source
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Company· 1
Investor· 1
Founders / team· 3
Funding history
- 2026-10-23Series E$237M
Investors · Bristol Myers SquibbSource · pathos.com ↗
- 2025-05Series D+$365M
Source · SVTR Weekly #105
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Pathos AI
Uses artificial intelligence and robotic automation to accelerate the development of targeted therapies for solid tumors
Series D+ · $602M · 2026-10
$602M
United States
BusinessLatest roundTotal raisedDate- Warp Sciences
AI and robotic automated labs for synthesizing and testing drug molecule variants
$215M · 2026-10 · Valuation $865M
$215MValuation $865M - Iambic Therapeutics
Uses AI to predict protein-ligand structures and generate molecular designs to discover new drugs
IPO · $462M · 2026-09
$462M - Vivodyne
Robotic automation to produce human tissue for faster drug testing
Series A · $40M · 2025-05
$40M
China
BusinessLatest roundTotal raisedDate- Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M - Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09 · Valuation $1.5B
$290MValuation $1.5B - Coherence Biotech Co. Ltd.
Lab automation: the Keystone™ benchtop all-in-one system combines culturing, intervention and microscopy imaging into uninterrupted multi-day cell/organoid experiments and uses AI vision to identify, count and track cells, generating structured experimental data for AI drug discovery
—
Europe
BusinessLatest roundTotal raisedDate- Causaly
AI platform that helps researchers accelerate drug development and testing
Series B · $60M · 2023-07
$60M - Healx
AI to discover and develop treatments for rare diseases
Undisclosed · $47M · 2024-08
$47M - CardiaTec
Uses AI and large-scale multi-omics data to discover new therapies for cardiovascular disease
Seed · $7M · 2024-09
$7M
Other / unspecified
BusinessLatest roundTotal raisedDate- Altis Labs
AI imaging biomarker platform across solid tumor types and therapeutic areas
Series A · $31M · 2026-09
$31M - Mana.bio
Uses AI to design lipid nanoparticles for delivering mRNA to specific parts of the body
Seed · $20M · 2023-10
$20M - Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Related coverage
Investors that may fit
General Catalyst
40 Life Sciences deals in the last 24 months · 7 at a nearby stage · 36 in Chicago Metro
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 3 at a nearby stage · 31 in Chicago Metro
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 10 at a nearby stage · 22 in Chicago Metro
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 6 at a nearby stage · 20 in Chicago Metro
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 8 at a nearby stage · 15 in Chicago Metro
Request intro →Lightspeed
17 Life Sciences deals in the last 24 months · 5 at a nearby stage · 15 in Chicago Metro
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.